Charles Schwab Investment Management Inc. Buys 24,953 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO)

Charles Schwab Investment Management Inc. raised its stake in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) by 13.0% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 217,550 shares of the company’s stock after purchasing an additional 24,953 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Soleno Therapeutics were worth $9,779,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of SLNO. US Bancorp DE bought a new position in shares of Soleno Therapeutics in the 4th quarter worth about $34,000. New York State Common Retirement Fund raised its position in shares of Soleno Therapeutics by 13.2% in the 4th quarter. New York State Common Retirement Fund now owns 7,717 shares of the company’s stock worth $347,000 after acquiring an additional 900 shares in the last quarter. Harbor Capital Advisors Inc. raised its position in shares of Soleno Therapeutics by 3.5% in the 4th quarter. Harbor Capital Advisors Inc. now owns 37,296 shares of the company’s stock worth $1,676,000 after acquiring an additional 1,248 shares in the last quarter. Avanza Fonder AB bought a new position in shares of Soleno Therapeutics in the 4th quarter worth about $76,000. Finally, Avior Wealth Management LLC bought a new position in shares of Soleno Therapeutics in the 4th quarter worth about $89,000. 97.42% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

SLNO has been the subject of several research analyst reports. Robert W. Baird reissued an “outperform” rating and issued a $72.00 price objective on shares of Soleno Therapeutics in a research report on Monday, December 2nd. Lifesci Capital raised Soleno Therapeutics to a “strong-buy” rating in a research report on Tuesday, February 4th. HC Wainwright reissued a “buy” rating and issued a $70.00 price objective on shares of Soleno Therapeutics in a research report on Monday, March 3rd. Finally, Stifel Nicolaus started coverage on Soleno Therapeutics in a research report on Wednesday, March 5th. They issued a “buy” rating and a $74.00 target price for the company. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $71.20.

Soleno Therapeutics Price Performance

Shares of Soleno Therapeutics stock opened at $49.11 on Friday. Soleno Therapeutics, Inc. has a one year low of $36.61 and a one year high of $60.92. The firm has a market capitalization of $2.25 billion, a price-to-earnings ratio of -14.79 and a beta of -1.70. The business has a 50-day simple moving average of $47.71 and a 200 day simple moving average of $49.77.

Soleno Therapeutics (NASDAQ:SLNO) last issued its earnings results on Wednesday, March 5th. The company reported ($1.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.41). On average, sell-side analysts expect that Soleno Therapeutics, Inc. will post -3.72 EPS for the current year.

Insider Buying and Selling at Soleno Therapeutics

In other Soleno Therapeutics news, insider Kristen Yen sold 2,340 shares of Soleno Therapeutics stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $46.18, for a total transaction of $108,061.20. Following the completion of the transaction, the insider now owns 76,605 shares in the company, valued at approximately $3,537,618.90. The trade was a 2.96 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Bhatnagar Anish sold 10,937 shares of Soleno Therapeutics stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $45.41, for a total value of $496,649.17. Following the transaction, the chief executive officer now owns 708,616 shares of the company’s stock, valued at $32,178,252.56. This trade represents a 1.52 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 17,360 shares of company stock worth $790,119. Insiders own 12.30% of the company’s stock.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.